Client News

CBOE-Listed SinglePoint Inc. (CBOE: SING) Provides Strategic Overview, Highlights Milestones Reached, and Expectations In 2024

Phoenix, Arizona—(Newsfile Corp. – January 5, 2024) – SinglePoint Inc. (CBOE: SING) (“SinglePoint” or “the Company”), a provider of renewable energy, energy supply, and healthy building solutions, provides an update highlighting 2023 accomplishments and its plans to increase shareholder value in 2024. After successfully listing on the CBOE BZX Exchange in December, SinglePoint enters the […]

NanoViricides (NYSE American:NNVC) to Present at the Biotech Showcase in San Fransisco

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 9, […]

SciSparc (Nasdaq: SPRC) and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc’s PEA TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) —  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on […]

Horizon Aircraft Announces Board of Directors for Post-Merger Public Company

~ Board Announced in Anticipation of January 2024 Merger Between Horizon Aircraft and Pono Capital Three, Inc. ~ ~ Horizon’s Chief Executive Officer Brandon Robinson Appointed Chairman ~ ~ Board Consists of Experienced Leaders in the Aviation and Innovative Technology Industries with Traditional Corporate Business Management ~ TORONTO, Jan. 02, 2024 (GLOBE NEWSWIRE) — Robinson […]

Trio Petroleum Corp (NYSE American: TPET) Announces Commencement of Production of Two Wells – its HV-1 Confirmation Well and its HV-3A Discovery Well in the South Salinas Project

Bakersfield, CA, Jan. 03, 2024 (GLOBE NEWSWIRE) — Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today provided updates on its HV-1 confirmation well (“HV-1”) and its HV-3A discovery well (“HV-3A”) in the Company’s South Salinas Project. On December 27, the Company moved a rig onto location […]

Inspire Veterinary Partners (NASDAQ:IVP) Announces Opening of Newly Relocated and Expanded Family Pet Care Animal Hospital in Sugarland, Texas

New hospital design represents model for future upgrades across the IVP platform State-of-the-art facility has been designed to elevate service to customers while creating an efficient and attractive workplace environment for employees VIRGINIA BEACH, VA / ACCESSWIRE / January 3, 2024 / Inspire Veterinary Partners, Inc. (NASDAQ:IVP) (“Inspire” or the “Company”), an owner and provider […]

Boston Solar (CBOE: SING) Named First US Partner for Energizer Solar, Pioneering Renewable Energy Solutions in the American Market

BOSTON, MA / ACCESSWIRE / January 2, 2024 / In a groundbreaking move that marks a significant milestone in the renewable energy sector, Boston Solar, a subsidiary of SinglePoint Inc. (CBOE:SING), a leader in solar energy solutions, has joined forces with Energizer Solar to launch Energizer Solar renewable energy solutions starting with the Energizer Solar […]

NKGen Biotech, Inc. (Nasdaq: NKGN) Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

NKGen Biotech’s autologous clinical program product candidate, SNK01, demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease (“AD”) in its Phase 1 dose-escalation safety trial. SNK01 consists of a non-genetically modified NK cell product with enhanced cytotoxicity and activating receptor expression for the treatment of moderate AD. Initial patient in this Phase […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.